CTOs on the Move


 
Opiant Pharmaceuticals` team of industry and addiction experts are dedicated developing treatments for addiction, overdose, and related disorders for the mass market. Our first product NARCAN® Nasal Spray became available in the United States and Canada through our commercial partner, Adapt Pharma.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.opiant.com
  • 233 Wilshire Boulevard Suite 280
    Santa Monica, CA USA 90401
  • Phone: 424.252.4756

Executives

Name Title Contact Details

Similar Companies

Biocon

Biocon Limited, publicly listed in 2004, is India`s largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high.

Sizewise

We offer bariatric and non-bariatric medical equipment including bed frames, therapeutic mattresses, and mobility items for patients of all ages.

Cychem

Cychem is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Smiles Dental

Welcome to Smiles Dental! Were proud to offer One of a Kind(ness) dentistry at our convenient offices across Washington and Oregon.

ORIC Pharmaceuticals

ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.